PFE

Pfizer Inc.

A maker of medicines and vaccines, Pfizer produces well-known drugs like the blood thinner Eliquis, the Prevnar pneumonia vaccines, the Covid shot Comirnaty, the antiviral Paxlovid, and cancer treatments Ibrance and Xtandi, used by patients around the world. It was founded in 1849 in Brooklyn by German cousins Charles Pfizer, a chemist, and Charles Erhart, a confectioner, who began by coating a bitter worm medicine in almond-flavored toffee candy. Its most famous discovery, the erectile-dysfunction drug Viagra, was a happy accident—originally developed as a heart medication for angina.

CUSIP: 717081103HealthcareUS14 holders

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Damelio Frank AExecutive Vice President · 6 transactions

555.9K-8.5%

as of Feb 2022

Granted 280.9K

Young John DGroup President · 11 transactions

422.1K-9.4%

as of Nov 2021

Sold 150.0K

Bourla AlbertChairman & CEO, Director · 20 transactions

394.7K+133.8%

Granted 1.79M

Dolsten MikaelPresident R&D · 27 transactions

323.7K+132.1%

as of Feb 2024

Granted 452.3K · Sold 123.6K

Lankler Douglas MExecutive Vice President · 35 transactions

284.3K+87.3%

Granted 756.1K · Sold 78.3K

Susman SallyExecutive Vice President · 36 transactions

169.8K+26.1%

as of Mar 2025

Granted 502.1K · Sold 44.3K

Boshoff ChristoffelPresident, R&D · 21 transactions

168.9K—

Granted 112.0K

Johnson Rady AExecutive Vice President · 26 transactions

127.2K+58.2%

as of Feb 2024

Granted 159.4K · Sold 19.0K

Pao WilliamExecutive Vice President · 2 transactions

97.8K—

as of Mar 2023

Granted 115.9K

Mackenzie Alexander RExecutive Vice President · 1 transaction

97.6K-40.3%

as of Dec 2021

Sold 41.4K

Sahni PayalExecutive Vice President · 24 transactions

97.4K+216.7%

Granted 138.2K · Sold 1.4K

Hwang AngelaPresident, Global Biopharma · 16 transactions

81.9K+17.4%

as of Feb 2023

Granted 111.4K · Sold 26.2K

de Germay AlexandreExecutive Vice President · 1 transaction

74.4K—

as of Feb 2024

Granted 74.4K

McDermott MichaelExecutive Vice President · 30 transactions

74.3K—

Granted 164.7K

Fonseca LidiaExecutive Vice President · 7 transactions

46.5K+16.9%

Granted 129.5K

Carapezzi William R JRExecutive Vice President · 8 transactions

41.1K-43.3%

as of May 2022

Granted 46.8K · Sold 32.9K

Denton David MChief Financial Officer & EVP · 3 transactions

37.9K—

as of May 2024

Granted 61.3K

Blaylock Ronald EDirector · 1 transaction

32.5K—

as of Feb 2025

Bought 19.5K

Damico Jennifer B.SVP & Controller · 44 transactions

31.4K+174.7%

Granted 131.2K · Sold 27.8K

Malik AamirExecutive Vice President · 2 transactions

29.5K—

as of Aug 2024

Granted 43.4K

Gottlieb ScottDirector · 4 transactions

10.0K+150%

as of Oct 2024

Bought 6.0K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Damelio Frank AExecutive Vice President · 6 transactions	-8.5%	555.9Kas of Feb 2022	280.9K	—	—
Young John DGroup President · 11 transactions	-9.4%	422.1Kas of Nov 2021	—	—	150.0K
Bourla AlbertChairman & CEO, Director · 20 transactions	+133.8%	394.7K	1.79M	—	—
Dolsten MikaelPresident R&D · 27 transactions	+132.1%	323.7Kas of Feb 2024	452.3K	—	123.6K
Lankler Douglas MExecutive Vice President · 35 transactions	+87.3%	284.3K	756.1K	—	78.3K
Susman SallyExecutive Vice President · 36 transactions	+26.1%	169.8Kas of Mar 2025	502.1K	—	44.3K
Boshoff ChristoffelPresident, R&D · 21 transactions	—	168.9K	112.0K	—	—
Johnson Rady AExecutive Vice President · 26 transactions	+58.2%	127.2Kas of Feb 2024	159.4K	—	19.0K
Pao WilliamExecutive Vice President · 2 transactions	—	97.8Kas of Mar 2023	115.9K	—	—
Mackenzie Alexander RExecutive Vice President · 1 transaction	-40.3%	97.6Kas of Dec 2021	—	—	41.4K
Sahni PayalExecutive Vice President · 24 transactions	+216.7%	97.4K	138.2K	—	1.4K
Hwang AngelaPresident, Global Biopharma · 16 transactions	+17.4%	81.9Kas of Feb 2023	111.4K	—	26.2K
de Germay AlexandreExecutive Vice President · 1 transaction	—	74.4Kas of Feb 2024	74.4K	—	—
McDermott MichaelExecutive Vice President · 30 transactions	—	74.3K	164.7K	—	—
Fonseca LidiaExecutive Vice President · 7 transactions	+16.9%	46.5K	129.5K	—	—
Carapezzi William R JRExecutive Vice President · 8 transactions	-43.3%	41.1Kas of May 2022	46.8K	—	32.9K
Denton David MChief Financial Officer & EVP · 3 transactions	—	37.9Kas of May 2024	61.3K	—	—
Blaylock Ronald EDirector · 1 transaction	—	32.5Kas of Feb 2025	—	19.5K	—
Damico Jennifer B.SVP & Controller · 44 transactions	+174.7%	31.4K	131.2K	—	27.8K
Malik AamirExecutive Vice President · 2 transactions	—	29.5Kas of Aug 2024	43.4K	—	—
Gottlieb ScottDirector · 4 transactions	+150%	10.0Kas of Oct 2024	—	6.0K	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.